<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00181883</url>
  </required_header>
  <id_info>
    <org_study_id>2004-P-001509</org_study_id>
    <nct_id>NCT00181883</nct_id>
  </id_info>
  <brief_title>Quetiapine for Mania In Preschool Children 4 to 6 Years of Age With Bipolar Disorder</brief_title>
  <official_title>Open-Label Study of Quetiapine for Mania In Preschool Children 4 to 6 Years of Age With Bipolar and Bipolar Spectrum Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an 8-week open-label study aimed at assessing the effectiveness and tolerability of&#xD;
      Quetiapine, in the treatment of preschool children aged 4 to 6 years with bipolar and bipolar&#xD;
      spectrum disorder. This is an exploratory, pilot study, seeking to determine whether&#xD;
      Quetiapine is efficacious and well tolerated in the treatment of preschoolers with pediatric&#xD;
      bipolar and bipolar spectrum disorder in this age group. The study results will be used to&#xD;
      generate hypotheses for a larger randomized controlled clinical trial with explicit&#xD;
      hypotheses and sufficient statistical power.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Seroquel is a psychotropic agent that affects multiple neurotransmitter receptors in the&#xD;
      brain: serotonin 5HT1A and 5HT2, dopamine D1 and D2, histamine H1 (IC50=30nM), and adrenergic&#xD;
      receptors.&#xD;
&#xD;
      This is an 8-week open-label study aimed at assessing the effectiveness and tolerability of&#xD;
      Quetiapine, in the treatment of preschool children aged 4 to 6 years with bipolar and bipolar&#xD;
      spectrum disorder. This is an exploratory, pilot study, seeking to determine whether&#xD;
      Quetiapine is efficacious and well tolerated in the treatment of preschoolers with pediatric&#xD;
      bipolar and bipolar spectrum disorder in this age group. The study results will be used to&#xD;
      generate hypotheses for a larger randomized controlled clinical trial with explicit&#xD;
      hypotheses and sufficient statistical power.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Bipolar Symptoms as Measured by Reduction in Young-Mania Rating Scale (Y-MRS) Total Score</measure>
    <time_frame>Baseline to 8 weeks</time_frame>
    <description>The Y-MRS is used to evaluate mania symptoms in children and adolescents. Items on the scale are rated from 0-4 or 0-8, with higher values indicating greater severity. The minimum (least severe) total score is 0, with the maximum (most severe) score is 60.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Bipolar Disorder</condition>
  <condition>Mania</condition>
  <arm_group>
    <arm_group_label>Quetiapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.5 - 5.0mg/kg PO BID quetiapine&#xD;
Other Names:&#xD;
Seroquel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>quetiapine</intervention_name>
    <description>2.5 - 5.0mg/kg PO BID quetiapine</description>
    <arm_group_label>Quetiapine</arm_group_label>
    <other_name>Seroquel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects, 4-6 years of age.&#xD;
&#xD;
          -  Subjects must have a DSM-IV diagnosis of bipolar I, bipolar II disorder or bipolar&#xD;
             spectrum disorder and currently displaying manic, hypomanic, or mixed symptoms (with&#xD;
             or without psychotic features) according to the DSM-IV based on clinical assessment&#xD;
             and confirmed by structured diagnostic interview (Kidd Schedule of Affective Disorders&#xD;
             and Schizophrenia Epidemiological Version). Bipolar spectrum disorder (or&#xD;
             sub-threshold bipolar disorder) is operationalized as having severe mood disturbance,&#xD;
             which meets DSM-IV Criteria A for bipolar disorder but meet fewer elements in criteria&#xD;
             B (only require 2 items for elation category and 3 for irritability).&#xD;
&#xD;
          -  Subjects and their legal representative must have a level of understanding sufficient&#xD;
             to communicate intelligently with the investigator and study coordinator, and to&#xD;
             cooperate with all tests and examinations required by the protocol.&#xD;
&#xD;
          -  Subjects and their legal representative must be considered reliable.&#xD;
&#xD;
          -  Each subject and his/her authorized legal representative must understand the nature of&#xD;
             the study. The subject's authorized legal representative must sign an informed consent&#xD;
             document.&#xD;
&#xD;
          -  Subjects must have an initial score on the Young Mania Rating Scale (Y-MRS) total&#xD;
             score of at least 20.&#xD;
&#xD;
          -  Subject must be able to participate in mandatory blood draws.&#xD;
&#xD;
          -  Subjects with comorbid Attention Deficit Hyperactivity Disorder (ADHD), Oppositional&#xD;
             Defiant Disorder (ODD), Conduct Disorder (CD), anxiety and depressive disorders will&#xD;
             be allowed to participate in the study provided they do not meet for any of the&#xD;
             exclusionary criteria.&#xD;
&#xD;
          -  For concomitant stimulant therapy used to treat ADHD, subjects must have been on a&#xD;
             stable dose of the medication for 1 month prior to study enrollment. The dose of the&#xD;
             stimulant therapy will not change throughout the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Investigator and his/her immediate family; defined as the investigator's spouse,&#xD;
             parent, child, grandparent, or grandchild.&#xD;
&#xD;
          -  Serious, unstable illness including hepatic, renal, gastroenterological, respiratory,&#xD;
             cardiovascular (including ischemic heart disease), endocrinologic, neurologic,&#xD;
             immunologic, or hematologic disease.&#xD;
&#xD;
          -  Uncorrected hypothyroidism or hyperthyroidism.&#xD;
&#xD;
          -  History of severe allergies or multiple adverse drug reactions.&#xD;
&#xD;
          -  Non-febrile seizures without a clear and resolved etiology.&#xD;
&#xD;
          -  Leukopenia or history of leukopenia without a clear and resolved etiology.&#xD;
&#xD;
          -  Judged clinically to be at serious suicidal risk.&#xD;
&#xD;
          -  Any other concomitant medication with primarily central nervous system activity other&#xD;
             than specified in Concomitant Medication portion of the protocol.&#xD;
&#xD;
          -  A non-responder or a history of intolerance to an adequate trial of Quetiapine(2&#xD;
             months or more at an adequate dose) as determined by the clinician.&#xD;
&#xD;
          -  Current diagnosis of schizophrenia.&#xD;
&#xD;
          -  Non English speaking subjects will not be allowed into the study for the following&#xD;
             reasons: a) the assessment instruments are not available and have not been adequately&#xD;
             standardized in other languages; b) our clinical trials facility is located in&#xD;
             Cambridge and not in the MGH main campus without the availability of translators; c)&#xD;
             psychiatric questionnaires and evaluations are taxing and adding the complexity of a&#xD;
             translator has the potential to make the patient experience even more exhausting.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>6 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet Wozniak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>July 19, 2011</results_first_submitted>
  <results_first_submitted_qc>March 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 6, 2012</results_first_posted>
  <last_update_submitted>March 9, 2012</last_update_submitted>
  <last_update_submitted_qc>March 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Janet Wozniak, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Psychiatry at Harvard Medical School and at Massachusetts General Hospital</investigator_title>
  </responsible_party>
  <keyword>children</keyword>
  <keyword>bipolar disorder</keyword>
  <keyword>quetiapine</keyword>
  <keyword>preschoolers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mania</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Quetiapine</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Limiting AEs</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Quetiapine</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Bipolar Symptoms as Measured by Reduction in Young-Mania Rating Scale (Y-MRS) Total Score</title>
        <description>The Y-MRS is used to evaluate mania symptoms in children and adolescents. Items on the scale are rated from 0-4 or 0-8, with higher values indicating greater severity. The minimum (least severe) total score is 0, with the maximum (most severe) score is 60.</description>
        <time_frame>Baseline to 8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Quetiapine</title>
          </group>
        </group_list>
        <measure>
          <title>Change in Bipolar Symptoms as Measured by Reduction in Young-Mania Rating Scale (Y-MRS) Total Score</title>
          <description>The Y-MRS is used to evaluate mania symptoms in children and adolescents. Items on the scale are rated from 0-4 or 0-8, with higher values indicating greater severity. The minimum (least severe) total score is 0, with the maximum (most severe) score is 60.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.5" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Quetiapine</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>suicidal ideation</sub_title>
                <description>1 subject was terminated due to a serious adverse event possibly related to study medication. The subject had an increase in underlying symptoms of bipolar disorder, experiencing passive suicidal ideation (also present before participation).</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3.3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>stomach ache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>agitation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>anxious/figety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>blurry vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>cold symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>daytime sleepiness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>depressed mood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>enlarged gland, right side of neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>enuresis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>epistasis (nose bleeding)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>flu</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>increased appetite</sub_title>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>insect bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>irritable</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>lethargy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>minor burn on arm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>pallor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>perseveration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>sedation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>sleepiness</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>slurred speech</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>teary</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>thirsty/dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>tiredness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>chin/elbow abrasions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>injury (fall)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>congested</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin irritation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>sunburn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Janet Wozniak, MD</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-503-1038</phone>
      <email>jwozniak@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

